Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12703116 | 0.87 | P2RX7 (0.37) | P2RX7KDM4EALDH1A1LMNAGAA | |
| SCHEMBL308304 | 0.82 | P2RX7 (0.38) | P2RX7ALDH1A1LMNA | |
| SCHEMBL308303 | 0.82 | P2RX7 (0.38) | P2RX7ALDH1A1LMNA | |
| SCHEMBL4555250 | 0.81 | ALDH1A1 (0.34) | P2RX7KDM4EALDH1A1LMNAGAA | |
| SCHEMBL4448219 | 0.81 | P2RX7 (0.47) | P2RX7KDM4E | |
| SCHEMBL13114613 | 0.79 | P2RX7 (0.53) | P2RX7KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL17577837 | 0.79 | P2RX7 (0.53) | P2RX7KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL305691 | 0.79 | P2RX7 (0.43) | P2RX7ALDH1A1GAA | |
| SCHEMBL305725 | 0.79 | P2RX7 (0.43) | P2RX7ALDH1A1GAA | |
| SCHEMBL3589094 | 0.78 | P2RX7 (0.49) | P2RX7KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
| WO-2007109192-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885KDM4E 4307/4885ALDH1A1 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.